Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15910863 | 0.95 | USP2 (0.32) | LMNAALDH1A1USP2CYP1A2TSHR | |
| SCHEMBL14909578 | 0.91 | USP2 (0.31) | LMNAALDH1A1USP2CYP1A2TSHR | |
| SCHEMBL343056 | 0.84 | LMNA (0.33) | LMNAALDH1A1MEN1POLBKMT2A | |
| SCHEMBL2873479 | 0.84 | LMNA (0.33) | LMNAALDH1A1MEN1POLBKMT2A | |
| SCHEMBL17363051 | 0.81 | LMNA (0.30) | LMNA | |
| SCHEMBL1930225 | 0.78 | DPP4 (0.31) | — | |
| SCHEMBL15910747 | 0.78 | — | — | |
| SCHEMBL17074177 | 0.76 | — | — | |
| SCHEMBL2725107 | 0.76 | TSHR (0.31) | LMNAALDH1A1USP2CYP1A2TSHR | |
| SCHEMBL8211731 | 0.76 | LMNA (0.42) | LMNAALDH1A1USP2CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3272749-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-24 | — | — | EP | disclosed |
| EP-2914594-B1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | Bayer Pharma AG (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-9624214-B2 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| EP-2914594-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-20140179672-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-26 | — | — | US | disclosed |
| WO-2014068099-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | WO | disclosed |
| US-8399449-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179672-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAICS | LMNA 252/4885ALDH1A1 1143/4885USP2 2283/4885 |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | LMNA 4534/4885ALDH1A1 745/4885USP2 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.